Research Interests
The Zhu Haibo group focuses on the development of small molecule drugs and the basic theory of exercise mimetics, including the body's metabolism and the rule of immune interaction. IMM-H007, an agonist of targeting cellular energy sensor, AMPK (AMP-activated protein kinase) has been successfully developed. Invention patents from 16 countries including China, the United States, Japan, South Korea, and the European Union were obtained and achieved the market-based transfer. This project has been granted by multiple national projects.
